Advertisement
Screener

Panacea Life Sciences Holdings, Inc. (PLSH) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3

1.7 / 5 stars · 12/36 Roast Me

Panacea Life Sciences Holdings, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3

Panacea Life Sciences Holdings, Inc. (PLSH) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 of $469.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-29.

Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net

us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3 · last filed 2019-03-29

  • Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2018 was $469.00K, a 46.46% decline from fiscal 2017.
  • Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2017 was $876.00K.
Period endFair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 12 month
2018-12-31$469.00K
10-K · filed 2019-03-29
2017-12-31$876.00K
10-K · filed 2019-03-29